Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rt-PA versus standard treatment for COVID-19-induced ARDS
IRCT20200415047080N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of enoxaparin in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: oxygenation, mechanical ventilation free days and 3 more. Started Sep 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20200415047080N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200415047080N1.